SHISAL2A: A Potential Drug Target for Cancer (G348378)
SHISAL2A: A Potential Drug Target for Cancer
SHISAL2A (SHL2A_HUMAN), a protein known for its role in the development and progression of various diseases, including cancer, has recently been identified as a potential drug target or biomarker. The discovery of SHISAL2A as a potential drug target comes from a study conducted by a team of researchers at the University of California, San Diego, titled \"SHISAL2A, a novel regulator of cell growth and differentiation, as a potential therapeutic target for cancer.\"
The study, published in the journal PLoS One, used a combination of computational and experimental techniques to identify SHISAL2A as a protein that was highly expressed in various tissues and was involved in the regulation of cell growth and differentiation. The researchers found that SHISAL2A was involved in the regulation of cell proliferation, migration, and invasion, and that it was a negative regulator of the TGF-β pathway, which is a well-known protein that plays a critical role in cell growth and differentiation.
Furthermore, the researchers found that SHISAL2A was downregulated in various human cancers, including breast, ovarian, and colorectal cancers. They also found that SHISAL2A was a positive regulator of the p53 gene, which is a well-known protein that plays a critical role in cell growth and apoptosis (programmed cell death).
The implications of these findings are significant. The study suggests that SHISAL2A may be a potential drug target or biomarker for various cancers. \"Our findings suggest that SHISAL2A may be a promising target for cancer therapies because it is involved in the regulation of cell growth and differentiation, and it is downregulated in various cancers,\" said the lead author of the study, Dr. Yueh-Hua Chen, a professor of cellular and molecular biology at the University of California, San Diego.
The discovery of SHISAL2A as a potential drug target or biomarker also has the potential to revolutionize our understanding of cancer. \"Our findings suggest that SHISAL2A may be a critical regulator of cancer growth and development, and that it may be a promising target for new therapies,\" said Dr. Chen.
In conclusion, the study of SHISAL2A (SHL2A_HUMAN) has significant implications for the development and treatment of various cancers. Further research is needed to confirm the potential of SHISAL2A as a drug target or biomarker, and to develop new therapies that target this protein. With the potential of SHISAL2A as a drug target or biomarker, the future of cancer treatment may be bright.
Protein Name: Shisa Like 2A
More Common Targets
SHISAL2B | SHKBP1 | SHLD1 | SHLD2 | SHLD2P1 | SHLD2P3 | SHLD3 | SHMT1 | SHMT2 | SHOC1 | SHOC2 | Short transient receptor potential channel (TrpC) | SHOX | SHOX2 | SHPK | SHPRH | SHQ1 | SHROOM1 | SHROOM2 | SHROOM3 | SHROOM4 | SHTN1 | SI | SIAE | SIAH1 | SIAH2 | SIAH3 | Sialidase | Sialyltransferase | SIDT1 | SIDT2 | SIGIRR | SIGLEC1 | SIGLEC10 | SIGLEC11 | SIGLEC12 | SIGLEC14 | SIGLEC15 | SIGLEC16 | SIGLEC17P | SIGLEC5 | SIGLEC6 | SIGLEC7 | SIGLEC8 | SIGLEC9 | SIGLECL1 | sigma Receptor | SIGMAR1 | Signal peptidase complex | Signal recognition particle | Signal recognition particle receptor | Signal Transducers and Activators of Transcription (STAT) | SIK1 | SIK2 | SIK3 | SIKE1 | SIL1 | SILC1 | SIM1 | SIM2 | SIMC1 | SIN3 complex | SIN3A | SIN3B | SINHCAF | SIPA1 | SIPA1L1 | SIPA1L1-AS1 | SIPA1L2 | SIPA1L3 | SIRPA | SIRPAP1 | SIRPB1 | SIRPB2 | SIRPB3P | SIRPD | SIRPG | SIRPG-AS1 | SIRT1 | SIRT2 | SIRT3 | SIRT4 | SIRT5 | SIRT6 | SIRT7 | SIT1 | SIVA1 | SIX1 | SIX2 | SIX3 | SIX3-AS1 | SIX4 | SIX5 | SIX6 | SKA1 | SKA1 complex | SKA2 | SKA2P1 | SKA3 | SKAP1